LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Search

Ocular Therapeutix Inc

Geschlossen

BrancheGesundheitswesen

14.55 -0.68

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.34

Max

14.81

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.6M

-69M

Verkäufe

1.1M

15M

EPS

-0.38

Gewinnspanne

-477.296

Angestellte

274

EBITDA

-1.6M

-65M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+62.24% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1B

3.4B

Vorheriger Eröffnungskurs

15.23

Vorheriger Schlusskurs

14.55

Nachrichtenstimmung

By Acuity

100%

0%

352 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Ocular Therapeutix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Dez. 2025, 16:42 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

12. Dez. 2025, 23:49 UTC

Akquisitionen, Fusionen, Übernahmen

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. Dez. 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. Dez. 2025, 22:32 UTC

Ergebnisse

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Dez. 2025, 20:45 UTC

Ergebnisse

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. Dez. 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. Dez. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. Dez. 2025, 19:23 UTC

Ergebnisse

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. Dez. 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. Dez. 2025, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. Dez. 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. Dez. 2025, 17:49 UTC

Ergebnisse

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. Dez. 2025, 17:34 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12. Dez. 2025, 17:33 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12. Dez. 2025, 17:33 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12. Dez. 2025, 17:32 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12. Dez. 2025, 17:31 UTC

Akquisitionen, Fusionen, Übernahmen

Orange to Buy the Stake for EU4.25B in Cash

12. Dez. 2025, 17:24 UTC

Market Talk

Argentina Predicts Record Wheat Crop -- Market Talk

12. Dez. 2025, 17:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

12. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Dez. 2025, 17:18 UTC

Market Talk
Ergebnisse

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12. Dez. 2025, 17:09 UTC

Market Talk

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12. Dez. 2025, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Dez. 2025, 16:47 UTC

Market Talk

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12. Dez. 2025, 16:39 UTC

Market Talk

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

12. Dez. 2025, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

12. Dez. 2025, 16:15 UTC

Ergebnisse

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

12. Dez. 2025, 15:35 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. Dez. 2025, 14:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Ocular Therapeutix Inc Prognose

Kursziel

By TipRanks

62.24% Vorteil

12-Monats-Prognose

Durchschnitt 23.8 USD  62.24%

Hoch 31 USD

Tief 20 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ocular Therapeutix Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

11

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

6.97 / 7.62Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

352 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat